Bayern Kapital provides €2m for Numares Health series-C

Bayern Kapital invested in the group via its Bavarian growth fund Wachstumsfonds Bayern, providing €2m for the round. 

This new round of funding aims to help the company carry out its international expansion plans and tap into new markets. After introducing its technology in the US, Numares Health is now looking at the rest of Europe and Asia. Numares added it would keep expanding its test pipeline to increase its therapeutic spectrum.

Bayern Kapital, as well as Frankfurt-based government-owned KfW Bankengruppe, have been supporting the group since inception and through every funding round completed since 2006.

Previous funding
Numares Health has so far gathered around $29.5m through venture funding, having completed five funding rounds since 2006.

In 2006, the company received $2.51m in a venture round from Bayern Kapital and state-owned KfW Bankengruppe. Three years later, it received an extra €4m.
In October 2011, a third venture round brought together Bayern, KfW, and SHS (SHS Gesellschaft für Beteiligungsmanagement).

Bayern and KfW also supported the group in a $9.5m series-B round in 2012, and contributed to the latest round.

Company
Based in Regensburg and with an additional operation in the US, Numares Health is specialised in in-vitro diagnostic systems. The company develops and markets integrated test systems for human diagnostics based on nuclear magnetic resonance spectroscopy.

The company employs about 50 people. In the past two years, more than 900,000 tests were billed and 16 of the company's Axinon test systems were sold.

People
Bayern Kapital – Dr Georg Ried (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Expansion
• Healthcare
• Germany
• DACH
• Venture